Unmasking the role of tumor microenvironment in the advanced stage of cancer treatment to mitigate risks during chemotherapy
Biochemical Pharmacology · 2026
DOI: 10.1016/j.bcp.2026.117754 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Anchala Kumari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Raebareli, Lucknow 226002, India. Hauptthemen laut MEDLINE: Tumor Microenvironment, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 188 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India, National Institute of Pharmaceutical Education and Research, Raebareli.
Themen: Onkologische Pflege
Abstract (Originalsprache)
The complexity of the tumor microenvironment in advanced-stage cancer critically diminishes the activity of chemotherapy, often reducing its efficacy to a point where the inherent risks become clinically unwarranted. This review "unmasks" the tumor microenvironment as a sophisticated barrier system driven primarily by hypoxia, i.e. severe oxygen deprivation. Hypoxia stabilizes master-regulators, including hypoxia-inducible factor-1α, which actively induce multidrug resistance. Specifically, hypoxia-inducible factor-1α orchestrates drug expulsion from the cancer cell via efflux pumps and enhances cellular repair of drug-induced DNA damage, functionally neutralizing cytotoxic agents. This resistance is compounded by tumor heterogeneity, which promotes the selection of aggressive, drug-evading subclones, and by hypoxia-induced degradation of the major histocompatibility complex class I, rendering cancer cells invisible to the immune system. Translational challenges, such as the mixed efficacy of hypoxia-activated prodrugs, highlight the urgent need for robust diagnostics to accurately verify tumor microenvironment conditions. To restore therapeutic efficacy and mitigate the risks of ineffective treatments, a paradigm shift is necessary: integrating tumor microenvironment-targeted agents (such as hypoxia-inducible factor-2α inhibitors) with adaptive dosing strategies guided by real-time molecular monitoring, including liquid biopsies and hypoxia-PET imaging. This integrated strategy is essential for achieving durable patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Raebareli, Lucknow 226002, India.
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Raebareli, Lucknow 226002, India. Electronic address: director@niperraebareli.edu.in.
- Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Raebareli, Lucknow 226002, India. Electronic address: nidhi.srivastava@niperrbl.ac.in.
Förderung
- Department of Biotechnology, Ministry of Science and Technology, India
- Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India
- National Institute of Pharmaceutical Education and Research, Raebareli
Zitieren
APA
Kumari, A., Meher, N., Dey, A., Awasthi, S., Saraf, S. A., & Srivastava, N. (2026). Unmasking the role of tumor microenvironment in the advanced stage of cancer treatment to mitigate risks during chemotherapy. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.117754
Vancouver
Kumari A, Meher N, Dey A, Awasthi S, Saraf SA, Srivastava N. Unmasking the role of tumor microenvironment in the advanced stage of cancer treatment to mitigate risks during chemotherapy. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.117754
BibTeX
@article{Kumari2026,
author = {Kumari, Anchala and Meher, Niranjan and Dey, Abhishek and Awasthi, Saurav and Saraf, Shubhini A and Srivastava, Nidhi},
title = {Unmasking the role of tumor microenvironment in the advanced stage of cancer treatment to mitigate risks during chemotherapy},
journal = {Biochemical Pharmacology},
year = {2026},
doi = {10.1016/j.bcp.2026.117754}
}
EUVIMED